What does the research actually say about cannabis and migraine treatment? This guide breaks down the evidence, THC vs. CBD, terpene questions, product formats, and practical tips for Florida medical cannabis patients.

Chronic illness care is rarely about one symptom. This guide explains how cannabis may fit into a broader management plan, what the evidence actually says, and which Florida product formats are worth a closer look.

Cannabis gets talked about like it’s one big category: plant, oil, gummies, vape, done. But when the conversation turns to epilepsy, the real story is a lot more specific. In plain English: the FDA has not approved “cannabis” broadly for epilepsy. What it has approved is Epidiolex, a prescription oral solution made with purified cannabidiol (CBD), for a short list of seizure disorders. That distinction matters—a lot.

Here’s the Green Dragon-style takeaway up front: this is general cannabis education, not medical advice. If epilepsy is part of your life—or part of your family’s life—the safest move is to treat cannabinoids like real compounds with real upside, real risks, and real interaction potential. That means neurologist first, product second. Green Dragon’s own patient education leans the same way: practical, measured, and safety-first, especially when medications and complex conditions are involved.

What terpene degradation really means

“Degradation” is a bucket term for a few different processes:

• Evaporation (volatilization): Many terpenes are highly volatile, meaning they readily leave the plant material and disperse into air—especially when warm. A storage study on terpene-infused pre-rolls showed terpene evaporation rates rise with higher temperatures and stronger light exposure.

• Oxidation: Oxygen can react with terpenes and other compounds over time, changing the aroma profile and potentially dulling the experience.